Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary fibrosis.

David A Zisman1, Michael P Keane, John A Belperio

  • 1Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at University of Califonia, Los Angeles, CA, USA.

Methods in Molecular Medicine
|September 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Effectiveness of Single Versus Bilateral Lung Transplantation in Dually Listed Recipients: A National Target Trial.

Annals of surgery·2026
Same author

Current insight into molecular mechanisms of Lymphangioleiomyomatosis.

American journal of respiratory cell and molecular biology·2026
Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026
Same author

Latent Class Analysis Identifies Pulmonary Function Trajectory Phenotypes in Lung Transplant Recipients with Chronic Allograft Dysfunction.

medRxiv : the preprint server for health sciences·2026
Same author

Utility of donor-derived cell-free DNA testing after lung transplantation in the precision medicine era.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis.

Respiratory research·2026

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with poor prognosis. Current therapies offer limited benefit, driving research into novel treatments targeting disease mechanisms.

Area of Science:

  • Pulmonology
  • Pathology
  • Medical Research

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by usual interstitial pneumonia (UIP) histology.
  • Prevalence is estimated at 35,000-55,000 cases in the US and appears to be increasing.
  • Risk factors include smoking, environmental exposures, GERD, certain drugs, diabetes, infections, and genetics.

Purpose of the Study:

  • To review the current understanding of IPF, including its diagnosis, prognosis, and therapeutic challenges.
  • To highlight the limitations of conventional therapies and the need for novel treatment strategies.

Main Methods:

  • Review of existing literature on IPF diagnosis, risk factors, natural history, and treatment outcomes.
  • Analysis of factors predicting poor prognosis in IPF patients.

Related Experiment Videos

  • Evaluation of current and emerging therapeutic approaches.

    • Main Results:

    • IPF diagnosis requires a comprehensive assessment including history, physical exam, imaging, and potentially biopsy.
    • Median survival is less than 3 years, with common causes of mortality including respiratory failure and cardiovascular disease.
    • Conventional treatments offer marginal benefits, and lung transplantation is an option for refractory cases.

    Conclusions:

    • IPF has a poor prognosis with limited response to conventional anti-inflammatory therapies.
    • Emerging therapeutic strategies focus on inhibiting epithelial injury, modulating cytokines, and targeting fibroblast activity.
    • Further research into novel treatments is crucial for improving outcomes in IPF patients.